USPTO serial 97146181
RAPIDZ
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LE, KIEU-NHI NGOC
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RAPIDZ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Viola T. Kung
Viola T. Kung PERKINS COIE LLPP.O. BOX 2608SEATTLE, WA 98111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Preparations for diagnostic purposes other than for medical or veterinary purposes; diagnostic substances other than for medical or veterinary use; diagnostic substances for use in lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays, other than for medical or veterinary use; lateral flow preparation kits comprised of chemically treated non-medical test strips for detecting disease other than for medical or veterinary use, reagents for scientific and research use, sample and reagent vials, and specimen collection tools | ACTIVE | — |
| 005 | Diagnostic kits comprised of medical diagnostic reagents and assays for analysis of bodily fluids for use in disease detection, namely, infectious diseases, cancer, cardiovascular diseases, fertility conditions, pulmonary diseases, brain diseases, liver diseases, bone diseases, diabetes, autoimmune diseases, thyroid diseases, and kidney diseases; diagnostic kits, namely, test strips and appropriate reagents and buffers for determining the presence or concentration of biomolecules in bodily fluids for use in disease detection, namely, infectious diseases, cancer, cardiovascular diseases, fertility conditions, pulmonary diseases, brain diseases, liver diseases, bone diseases, diabetes, autoimmune diseases, thyroid diseases, and kidney diseases; medical diagnostic test strips for analysis of bodily fluids; medical diagnostic test strips for use in detecting the presence of analytes; medical diagnostic test strips for use in detecting indicators of diseases, such indicators being enzymes, antigens, antibodies, and nucleic acids; medical diagnostic test strips for lateral flow devices; medical diagnostic test strips for lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays; lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays for detecting infectious diseases, cancer, cardiovascular diseases, fertility conditions, pulmonary diseases, brain diseases, liver diseases, bone diseases, diabetes, autoimmune diseases, thyroid diseases, and kidney diseases; preparations for medical or veterinary purposes, namely, reagents and buffers for diagnostics preparations for medical or veterinary purposes, namely, reagents and buffers for use in detecting antigens or antibodies in liquid samples; diagnostic reagents for medical or veterinary use; buffer solutions for medical or veterinary use; diagnostic preparations for medical and veterinary use; pharmaceutical preparations for detecting infectious diseases, cancer, cardiovascular diseases, fertility conditions, pulmonary diseases, brain diseases, liver diseases, bone diseases, diabetes, autoimmune diseases, thyroid diseases, and kidney diseases or monitoring therapeutic drug effectiveness and reactivity; diagnostic substances for medical or veterinary use; lateral flow test strips for use in the field of point-of-care, at home testing, and professional laboratories for analysis of bodily fluids, namely, blood, urine, saliva, and sweat; lateral flow preparation kits comprised of medical diagnostic test strips for use in the field of point-of-care, at home testing, and professional laboratories for analysis of bodily fluids, namely, blood, urine, saliva, and sweat, medical diagnostic reagents, vials for medical specimens and reagents, swabs for medical use, and medical specimen collecting tools | ACTIVE | — |
| 009 | Instruments for analysis of bodily fluids for scientific or research purposes; scientific instruments for determining the presence or concentration of biomolecules in bodily fluids; instruments for using lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays for scientific or research purposes; devices other than for medical or veterinary purposes, namely, cartridges for receiving lateral flow test strips to be analyzed for scientific or research purposes; assay readers other than for medical or veterinary use, namely, lateral flow readers; assaying instruments, namely, laboratory instruments in the nature of assay readers for scientific or research purposes; bioassay devices, namely, bioassay analyzers for measuring, testing, and analyzing samples of bodily fluids and parts therefor, for scientific or research purposes; devices for confirming the presence or absence of an analyte, other than for medical purposes; diagnostic devices that employ immunoassay technology to detect the presence of analytes in bodily fluids for scientific or research purposes; diagnostic equipment, namely, lateral flow readers, lateral flow test strips, and lateral flow preparation kits for scientific or research purposes comprised of droppers for laboratory use, scientific research specimen collection devices comprised of swabs and capillaries for the collection of bodily fluids being blood and urine, and buffer | ACTIVE | — |
| 010 | Instruments for analysis of bodily fluids for medical or veterinary purposes; medical instruments for determining the presence or concentration of biomolecules in bodily fluids; instruments for using lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays for medical or veterinary purposes; devices for medical or veterinary purposes, namely, cartridges for receiving lateral flow test strips to be analyzed for diagnostic purposes; assay readers for medical or veterinary use, namely, lateral flow readers; devices for carrying out diagnostic tests for medical purposes; devices for confirming the presence or absence of an analyte for medical purposes; medical diagnostic devices that employ immunoassay technology to detect the presence of analytes in bodily fluids; medical diagnostic equipment, namely, lateral flow readers | ACTIVE | — |
| 042 | Scientific services, namely, detection and analysis of analytes in bodily fluids; scientific and clinical research in the field of biomolecules; scientific and clinical research in the fields of lateral flow readers, lateral flow test strips, and lateral flow preparation kits; scientific and clinical research in the fields of lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays; biological research; biochemical research; research and development services in the field of reagents; research and development services in the fields of lateral flow readers, lateral flow test strips, and lateral flow preparation kits; research and development services in the fields of lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays; research and development services in the field of diagnostic instruments | ACTIVE | — |
| 044 | Medical services, namely, diagnostic testing for analytes in bodily fluids; medical diagnostic testing relating to human health; medical services related to immunodiagnostic testing; medical testing services for diagnostic or treatment purposes; medical testing services relating to the diagnosis or treatment of disease; medical testing services, namely, conducting of lateral flow assays, lateral flow immunoassays, and lateral flow immunochromatographic assays for diagnostic or treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Access Medical Systems
- Other trademarks owned by Access Medical Systems
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RAPIDZ
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 30, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 30, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 23, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 22, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 22, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 22, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 21, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 21, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 21, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 28, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 3, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 3, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 13, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 29, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 29, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 29, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 29, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 29, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 22, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 21, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 21, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 26, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 26, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 26, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 25, 2023 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 18, 2023 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Apr 4, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 3, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 2, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 2, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 9, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 2, 2021 | NWAP | NEW APPLICATION ENTERED | — |